Performance Verification of High Sensitivity Analyzer for TAT, PIC, TM, and t-PAIC [0.03%]
高灵敏度TAT、PIC、TM和t-PAIC检测试剂盒的性能验证研究
Yanhong Liu,Bo Guo,Guanghui Chen et al.
Yanhong Liu et al.
Background: Thrombin-antithrombin complex (TAT), a2-plasmininhibitor-plasmin complex (PIC), thrombomodulin (TM), tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) has been increasingly applied ...
Corrigendum: National Early Warning Score for Predicting Clinical Outcome of Acute Pulmonary Embolism in Intermediate-High Risk Patients [0.03%]
急性肺栓塞患者Intermediate-high风险患者急性肺栓塞临床转归的早期预警评分(corrigendum)
Audrey J C Overgaauw,Esther J Nossent,Lilian J Meijboom et al.
Audrey J C Overgaauw et al.
[This corrects the article DOI: 10.1055/a-2719-9061.]. The Author(s). This is an open access article published by Thieme under the terms of the Creative ...
Trends and Predictors of Vena Cava Filter Use (2004-2023): A Swiss Nationwide Epidemiological Study [0.03%]
2004年至2023年期间肺静脉滤器使用趋势及预测因素的全国流行病学研究
Simon Wolf,Pilar Müller,Silvia Cardi et al.
Simon Wolf et al.
Background: Recent data on inferior vena cava filter (IVCF) placement mainly originate from the United States, with limited evidence from Europe. Methods:...
Pharmacokinetic Evidence Supporting Subcutaneous Use of Protein C Concentrate in Patients with Protein C Deficiency [0.03%]
蛋白C缺乏症患者的蛋白C浓缩剂皮下给药的药代动力学证据支持
Zhaoyang Li,Inmaculada C Sorribes,Jennifer Schneider et al.
Zhaoyang Li et al.
Background: Protein C concentrate (Ceprotin®; Baxalta US Inc., a Takeda company, Cambridge, MA; Takeda Manufacturing Austria AG, Vienna, Austria) is approved for intravenous (IV) use in severe congenital protein C defici...
National Early Warning Score for Predicting Clinical Outcome of Acute Pulmonary Embolism in Intermediate-High Risk Patients [0.03%]
用于中高危急性肺栓塞患者的预后评估及临床转归的预警评分系统研究
Audrey J C Overgaauw,Esther J Nossent,Lilian J Meijboom et al.
Audrey J C Overgaauw et al.
Background: Although the European Society of Cardiology (ESC) predicts mortality in acute pulmonary embolism (PE), it may overtriage the level of clinical monitoring needed. The National Early Warning Score (NEWS) is used...
Fibrinolytic Capacity and Risk of Bleeding in Intensive Care Patients with Acute Kidney Injury [0.03%]
急性肾损伤重症监护患者的溶栓能力和出血风险
Rasmus R Mikkelsen,Christine L Hvas,Tua Gyldenholm et al.
Rasmus R Mikkelsen et al.
Background: Acute kidney injury (AKI) is common among intensive care unit (ICU) patients and is associated with increased bleeding risk. The impact of fibrinolysis in AKI-related bleeding has not been explored previously....
Association between Active Cancer and Risk of Thrombotic and Cardiovascular Outcomes in Outpatients with COVID-19: A CORONA-VTE Network Analysis [0.03%]
基于CORONA-VTE网络的分析：癌症与冠状病毒病(COVID-19)门诊患者血栓和心血管结局风险的关系：一项队列研究
Bridget McGonagle,Christie Greason,Darsiya Krishnathasan et al.
Bridget McGonagle et al.
Coronavirus disease 2019 (COVID-19) and active cancer are each independently associated with excess risk of thrombotic and cardiovascular events. However, data are limited regarding the risk of these events in outpatients with active cancer...
Daniel Kraemmer,Rafaela Vostatek,Marina Trappl et al.
Daniel Kraemmer et al.
Introduction: Hemophilia is a rare X-linked bleeding disorder leading to recurrent hemarthroses, hemophilic arthropathy, and impaired quality of life. A chronic lifelong disease, hemophilia might be associated with accele...
Mental Health, Work Productivity, and Quality of Life in People with Severe Haemophilia A Receiving Prophylaxis: Findings from the CHESS Data Platform [0.03%]
CHESS数据平台中重度甲型血友病患者心理健康、工作能力和生活质量的研究
Pratima Chowdary,Letizia Polito,Mark Oellerich et al.
Pratima Chowdary et al.
Background: Newer therapeutic options for people with severe haemophilia A (PwSHA), in addition to improved clinical and patient-reported outcomes (PROs), have offered more personalised treatment regimens. This analysis e...
A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles [0.03%]
纤溶酶原激活物抑制剂-1的当代综述：结构、功能、遗传构成和胞内/胞外作用
Jacob Wortley,Justin Vu,Neha Soogoor et al.
Jacob Wortley et al.
Plasminogen activator inhibitor type 1 (PAI-1) is the key regulator of the fibrinolytic system, thereby acting as a potent mediator in thrombosis. Plasminogen activators such as PAI-1 mediate the conversion of the inactive zymogen plasminog...